Evidence map›Paper›PMID 34341912›Full record

ReviewNeurocritical care2021

Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage.

Kathryn N Kearns, Natasha Ironside, Min S Park, Bradford B Worrall, Andrew M Southerland, Ching-Jen Chen, Dale Ding

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurocritical care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathryn N Kearns *Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Natasha Ironside *Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Min S ParkDepartment of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Bradford B WorrallDepartment of Neurology, University of Virginia Health System, Charlottesville, VA, USA.
Andrew M SoutherlandDepartment of Neurology, University of Virginia Health System, Charlottesville, VA, USA.
Ching-Jen ChenDepartment of Neurological Surgery, University of Virginia Health System, Charlottesville, VA, USA.
Dale DingDepartment of Neurosurgery, University of Louisville Health System, Louisville, KY, USA. daleding1234@gmail.com.ORCID 0000-0002-2627-446X
University of Virginia Health System · USUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients who survive the initial ictus of spontaneous intracerebral hemorrhage (ICH) remain vulnerable to subsequent injury of the perilesional parenchyma by molecular and cellular responses to the hematoma. Secondary brain injury after ICH, which contributes to long-term functional impairment and mortality, has emerged as an attractive therapeutic target. This review summarizes preclinical and clinical evidence for neuroprotective therapies targeting secondary injury pathways following ICH. A focus on therapies with pleiotropic antiinflammatory effects that target thrombin-mediated chemotaxis and inflammatory cell migration has led to studies investigating statins, anticholinergics, sphingosine-1-phosphate receptor modulators, peroxisome proliferator activated receptor gamma agonists, and magnesium. Attempts to modulate ICH-induced blood-brain barrier breakdown and perihematomal edema formation has prompted studies of nonsteroidal antiinflammatory agents, matrix metalloproteinase inhibitors, and complement inhibitors. Iron chelators, such as deferoxamine and albumin, have been used to reduce the free radical injury that ensues from erythrocyte lysis. Stem cell transplantation has been assessed for its potential to enhance subacute neurogenesis and functional recovery. Despite promising preclinical results of numerous agents, their outcomes have not yet translated into positive clinical trials in patients with ICH. Further studies are necessary to improve our understanding of the molecular events that promote damage and inflammation of the perihematomal parenchyma after ICH. Elucidating the temporal and pathophysiologic features of this secondary brain injury could enhance the clinical efficacy of neuroprotective therapies for ICH.

Indexed as

Brain EdemaBrain InjuriesNeuroprotective AgentsBlood-Brain BarrierCerebral HemorrhageHematomaHumansNeuroprotectionNeuroprotective AgentsClinical trialIntracerebral hemorrhageNeuroprotectionSecondary injuryStroke

Identifiers

PMID34341912
OpenAlexW3189432384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.